David Jentsch: Impulsivity, Addiction, and Diversity in Neuroscience

Added:

The Developmental Learning and Choice Model of Addiction

While neurobiologists like Dr. Jentsch emphasize biological predisposing factors such as innate impulsivity and D2 receptor deficits, critics of the brain-disease paradigm offer an alternative perspective: the Developmental Learning and Choice Model. Proponents like Marc Lewis and Carl Hart argue that addiction is not a chronic brain disease, but rather a deeply ingrained habit and developmental learning process. They contend that emphasizing neurobiology overlooks the profound impact of social, environmental, and economic factors—such as isolation, trauma, and systemic poverty—on human decision-making. From this viewpoint, traditional animal models of drug self-administration lack translational validity because they isolate subjects in barren environments, failing to capture how choice and viable life alternatives mitigate addictive behaviors in humans. Consequently, this counterpoint advocates for social, psychological, and harm-reduction interventions over purely pharmacological treatments targeting brain receptors.

Basic concepts of neurotransmission, specifically the function of dopamine as a key neurotransmitter in reward and motor pathways.
An understanding of G-protein coupled receptors (GPCRs), with a specific focus on the inhibitory nature and signaling pathways of D2 dopamine receptors.
The fundamental neurobiology of addiction, including the mesolimbic pathway (ventral tegmental area to nucleus accumbens) and how substances alter reward processing.
An introductory understanding of behavioral genetics, specifically how genetic variation contributes to individual differences in behavior and cognitive traits.
The purpose and methodological limitations of using traditional, inbred animal models in translational neuroscience and psychiatric research.
Advanced psychopharmacology, exploring how novel therapeutic agents target D2 and D3 dopamine receptors to treat impulsive-compulsive disorders.
The use of genetically diverse mouse populations (such as Collaborative Cross or Diversity Outbred) to better replicate human genetic heterogeneity in preclinical trials.
Translational neuroimaging techniques, such as Positron Emission Tomography (PET), to measure receptor availability and density in living human subjects with substance use disorders.
The application of precision psychiatry, using genetic and neurobehavioral biomarkers (like high-impulsivity phenotypes) to tailor addiction treatments.
Neuroethical and societal implications surrounding genetic screening for addiction vulnerability and the classification of behavioral traits as biomarkers.
217 views2likes37:27@stephenvmahler56Original Release: 2022-10-30

Addiction involves dysfunction in frontal cortical circuits that regulate inhibitory control over reward-seeking behaviors, with individual differences in baseline dopamine D2 receptor density strongly predicting susceptibility to substance use disorders; this relationship is evolutionarily conserved across species from mice to humans, highlighting the importance of using genetically diverse animal models to understand addiction mechanisms.